Treatment of Liver Cancer
- Chun-Yu Liu1,2,3,
- Kuen-Feng Chen4,5 and
- Pei-Jer Chen4,5,6
- 1Department of Medicine, Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei 112, Taiwan
- 2School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
- 3Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei 112, Taiwan
- 4Department of Medical Research, National Taiwan University College of Medicine, Taipei 112, Taiwan
- 5National Center of Excellence for Clinical Trial and Research, National Taiwan University College of Medicine, Taipei 112, Taiwan
- 6Graduate Institute of Molecular Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 112, Taiwan
- Correspondence: peijerchen{at}ntu.edu.tw
Abstract
Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer. Incidence of liver cancer varies geographically and parallels with the geographic prevalence of viral hepatitis. A number of staging systems have been developed, reflecting the heterogeneity of primary liver cancer, regional preferences, and regional variations in resectability or transplant eligibility. Multimodality treatments are available for this heterogeneous malignancy, and there are variations in the management recommendations for liver cancers across specialties and geographic regions. Novel treatment strategies have merged with the advance of new treatment modalities. This work focuses on reviewing the incidence, staging, and treatment of liver cancer.
- Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved
